Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

9 percent for placebo) and also for median increase in percentage of seizure-free days (7.4 percent, 9.3 percent, and 12.1 percent vs. 5.4 percent for placebo) for those entering the maintenance period.

The pooled results among all patients in the intent-to-treat analysis, including those who dropped out during the titration period, also demonstrated statistically significant reductions in seizure frequency at all doses studied compared to placebo:

-- Seizure frequency was reduced by 33.3 percent for the 200 mg/day group, 36.8 percent for the 400 mg/day group, and by 39.4 percent for the 600 mg/day group, compared with 18.4 percent for placebo (p<.05 for the 200 mg/day group and p<.0001 for the 400 and 600 mg/day groups vs. placebo).

-- Responder rates were 34.1 percent for 200 mg/day, 39.7 percent for 400 mg/day, and 39.6 percent for 600 mg/day, compared with 22.6 percent for placebo (p<.05 for the 200 mg/day group and p<.0001 for the 400 and 600 mg/day groups vs. placebo).

Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.196)

Steve Chung, MD, David Rudd, David Hebert, PhD, Pamela Doty

Barrow Neurological Institute, Phoenix, AZ; SCHWARZ BIOSCIENCES (a member of the UCB Group), Research Triangle Park, Raleigh, North Carolina

Lacosamide Efficacy is Independent of Concomitant AED(s) Treatment

This analysis evaluated pooled data from the placebo and 400 mg/day Vimpat(R) treatment groups of each trial by the most frequently used concomitant AEDs. The most commonly used concomitant AEDs for this patient population were carbamazepine, lamotrigine, levetiracetam, valproate, and oxcarbazepine.

Overall, reduction in seizure frequency was 36.8 percent for adjunctive treatment with Vimpat(R) 400 mg/day versus 18.4 percent for adjunctive treatment with placebo. When analyzed by individual concomitant AED use, Vimpa
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)...  Now available is a stem cell therapy that ... , located in Guadalajara, Mexico , ... new health option: stem cell therapies for sports ... suffer from joint and muscle injuries due to professional ... rotator cuff, tennis elbow, and knee injuries. Throughout life ...
(Date:7/24/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... Results Observed in CLL Patients Treated With Low ... or Synergistic in Combination with Established TherapeuticsPreclinical Mechanism ... Compared With Other TherapeuticsSEATTLE, May 14 Trubion ... today the acceptance of three data presentations on ...
... LAB TEST NOW(R), the first retail direct-access lab testing ... Atherotech, Inc., a Birmingham, Alabama-based CLIA-laboratory to provide the ... price. The VAP Cholesterol Test is an expanded cholesterol ... risk and is the first cholesterol test to directly ...
... 1 safety studies, and plans for Phase 2 studies ... to be presentedCINCINNATI, May 14 Ausio Pharmaceuticals, LLC, ... aging global population, will lead off the Bio(R) Business ... 9:00 AM in Atlanta, Georgia. Ausio has developed AUS-131, ...
Cached Biology Technology:Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 2Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 3Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 4Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 5Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 6VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 2VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 3Ausio Pharmaceuticals to Present at Bio(R) 2009 2
(Date:7/25/2014)... this false-color image from the Terra satellite show the different ... wildfires in Eastern Russia. The burn scars show up ... The wildfires have broken across the remote parts of Eastern ... image from the MODIS instrument, it is still possible ... Two recent image features noted below show the devastating number ...
(Date:7/25/2014)... WA Nearly 600 scientists from 25 countries ... Genetics Meeting organized by the Genetics Society of ... Washington in Seattle. The conference will feature close ... research results on topics including gene expression and ... emerging technologies, evolution, aging, and a variety of ...
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... Many students have difficulty understanding and explaining how ... teach the subject, researchers at Michigan State University ... from the molecular changes underlying an evolving characteristic ... The researchers, Peter J. T. White, Merle K. ...
... Parasites comprise a large proportion of the diversity of ... included in analyses or models of food webs. If ... however, their inclusion could fundamentally alter our understanding of ... PLOS Biology this week, Santa Fe Institute ...
... Titanic sailed through just over 100 years ago was very ... is increasing ocean temperatures and harming marine food webs. Nitrogen ... international research team has now completed the first global study ... chemistry, the nitrogen cycle, at the end of the last ...
Cached Biology News:Teaching complete evolutionary stories increases learning 2Does including parasites upset food web theory? Yes and no, says new paper 2Study of oceans' past raises worries about their future 2
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
WD-repeat protein 4...
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
...
Biology Products: